BRAF and targeted treatment for non-small cell lung cancer

Abstract

Kang Xiaoyan， Qu Liyan, Song Xia. BRAF and targeted treatment for non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(8): 625-627.

［1］黄志敏, 吴一龙. 非小细胞肺癌的BRAF基因突变及其临床意义［J］. 中国肺癌杂志, 2012, 15(3): 183-186. DOI： 10.3779/j.issn.1009-3419.2012.03.09. ［2］ Li S, Li L, Zhu Y, et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5 125 Chinese cohorts［J］. Br J Cancer, 2014, 110(11): 2812-2820. DOI: 10.1038/bjc.2014.210. ［3］ Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer［J］. Clin Cancer Res, 2013, 19(16): 4532-4540. DOI: 10.1158/10780432.CCR-13-0657. ［4］ Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small cell lung cancer harboring BRAF mutations［J］. J Clin Oncol, 2011, 29(26): 3574-3579. DOI: 10.1200/JCO.2011.35.9638. ［5］ Chen D, Zhang LQ, Huang IF, et al. BRAF mutations in patients with non-small cell lung cancer, a systematic review and metaanalysis［J］. PLoS One, 2014, 9(6): e101354.DOI: 10.1371/journal.pone.0101354. ［6］ Brustugun OT, Khattak AM, Tromborg AK, et al. BRAFmutations in non-small cell lung cancer［J］. Lung Cancer, 2014, 84(1): 36-38.DOI: 10.1016/j.lungcan.2014.01.023. ［7］ Alrifai D, Popat S, Ahmed M, et al. A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations［J］. Lung Cancer, 2013, 80(3): 339-340.DOI: 10.1016/j.lungcan.2013.02.002. ［8］ Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1［J］. Proc Natl Acad Sci USA, 2012, 109(31): E2127-2133. DOI: 10.1073/pnas.1203530109. ［9］ Robinson S, O′Shaughnessy J, CL C, et al. BRAF V600Emutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib［J］. Lung Cancer, 2014, 85(2): 326-330.DOI: 10.1016/j.lungcan.2014.05.009. ［10］ Gautschi O, Milia J, Cabarrou B, et al. Targeted therapy for patients with BRAFmutant lung cancer: results from the european EURAF cohort［J］. J Thorac Oncol, 2015, 10(10): 1451-1457.DOI: 10.1097/JTO.0000000000000625. ［11］Gibney G, Zager J. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies［J］. Expert Opin Drug Metab Toxicol, 2013, 9(7): 893-899.DOI: 10.1517/17425255.2013.794220. ［12］Planchard D, Kim TM, Mazieres J, et al. Dabrafenib in patient with BRAF V600Emutant advanced nonsmall cell lung cancer(NSCLC): a multicenter, open-label, phase Ⅱ trial(BRF113928)［J］. Ann Oncol, 2014, 25(suppl 4): v1-v41. ［13］Schmid S, Siano M, Joerger M, et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600Emutant bronchial adenocarcinoma［J］. Lung Cancer, 2015, 87(1): 85-87.DOI: 10.1016/j.lungcan.2014.11.008. ［14］Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer［J］. Cancer Discov, 2011, 1(1): 4453. DOI: 10.1158/21598274.CD-10-0010. ［15］Sereno M, Moreno V, Moreno Rubio J, et al. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation［J］. Anticancer Drugs, 2015, 26(9):1004-1007.DOI: 10.1097/CAD.0000000000000277. ［16］Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAFmutant non-small cell lung cancer［J］. J Thorac Oncol, 2013, 8(5): e41-42. DOI: 0.1097/JTO.0b013e31828bb1b3 ［17］Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy［J］. Br J Cancer, 2010, 102(12): 1724-1730.DOI: 10.1038/sj.bjc.6605714. ［18］Joshi M, Rice SJ, Liu X, et al. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer［J］. PLoS One, 2015, 10(2): e0118210.DOI: 10.1371/journal.pone.0118210. ［19］耿睿, 潘莉, 宋霞. 程序性死亡配体-1及其抑制剂在非小细胞肺癌中的研究进展［J］. 国际肿瘤学杂志, 2015, 42(8): 628-630. DOI： 103760/cma.j.issn.1673422X.2015.08.019

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203.
[10]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[11]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[12]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[13]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[14]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 137-142.
[15]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.

BRAF and targeted treatment for non-small cell lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments